Generic Name and Formulations:
Rifampin 120mg, isoniazid 50mg, pyrazinamide 300mg; tabs.
Indications for RIFATER:
Initial phase of the short-course (2 months) treatment of susceptible pulmonary tuberculosis.
≥15yrs: Take 1 hour before or 2 hours after a meal with glass of water. Take as single daily dose. ≤44kg: 4 tabs. 45–54kg: 5 tabs. ≥55kg: 6 tabs. Malnourished, predisposed to neuropathy (eg, alcoholics, diabetes), adolescents: concomitant Vit. B6 recommended. Following initial phase, treatment should be continued with rifampin and isoniazid for at least 4 months or longer if sputum or culture positive, if resistant organisms are present, or HIV positive.
<15yrs: not recommended.
Concomitant ritonavir-boosted saquinavir (increased risk of severe hepatotoxicity). Concomitant atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir. Rifamycin hypersensitivity. Severe hepatic damage. Severe adverse reactions to isoniazid (eg, drug fever, chills, arthritis). Acute liver disease of any etiology. Acute gout.
Increased risk of severe or fatal hepatitis; monitor, discontinue if signs of hepatic damage detected. Discontinue if hepatotoxicity or hyperuricemia accompanied by an acute gouty arthritis develops. Chronic liver disease. Alcohol abusers. Severe renal dysfunction; monitor. Diabetes. Not recommended for intermittent therapy (risk of renal hypersensitivity reactions; rare). Monitor for skin or hypersensitivity reactions (eg, SJS, TEN, DRESS); discontinue if occur. May stain body secretions and contact lenses. Obtain baseline LFTs, bilirubin, serum creatinine, CBC, platelets, blood uric acid; follow-up monthly. If hepatic impaired: monitor liver function (esp. SGPT/SGOT) prior to therapy and then every 2–4 weeks during. Perform eye exams prior to treatment, then periodically. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. Concomitant hepatotoxic agents: may cause fatal liver dysfunction. Concomitant alcohol may be associated with higher incidence of isoniazid hepatitis. Avoid tyramine- and histamine-containing foods, halothane. Monitor prothrombin time with concomitant anticoagulants. May potentiate anticonvulsants (eg, phenytoin), benzodiazepines, haloperidol, ketoconazole, theophylline, warfarin; adjust dose. May antagonize anticonvulsants, digoxin, antiarrhythmics, oral anticoagulants, antifungals, barbiturates, β-blockers, calcium channel blockers, chloramphenicol, clarithromycin, fluoroquinolones, cyclosporine, cardiac glycosides, clofibrate, diazepam, doxycycline, haloperidol, levothyroxine, oral or systemic hormonal contraceptives, methadone, oral hypoglycemics, dapsone, corticosteroids, narcotic analgesics, progestins, quinine, tacrolimus, theophylline, tricyclic antidepressants, zidovudine, atovaquone, enalapril, sulfasalazine. May be potentiated by atovaquone, probenecid, cotrimoxazole, para-aminosalicylic acid. May be antagonized by ketoconazole. CNS effects may be exaggerated with meperidine, cycloserine, disulfiram. Excess catecholamine stimulation or lack of levodopa effect with concomitant levodopa. Monitor renal function with concomitant enflurane. May inhibit diamine oxidase. May cause false (+) urine tests for opiates. May inhibit assays for serum folate and Vit. B12 (consider alternative methods). May interfere with Acetest and Ketostix. Separate from antacids by at least 1 hour.
Rifamycin + isonicotinic acid + nicotinamide analogue.
Headache, drowsiness, fatigue, ataxia, dizziness, inability to concentrate, mental confusion, visual disturbances, muscular weakness, pain in extremities, generalized numbness, peripheral neuropathy (esp. in slow inactivators), GI disturbances, abnormal LFTs, hepatitis (may be severe or fatal), bilirubinemia, jaundice, elevated BUN and serum uric acid, blood dyscrasias, pruritus, rash, fever, menstrual disturbances, hyperuricemia, gout, arthralgia, myalgia, severe hypersensitivity reactions (may be fatal), others.
Psychiatry Advisor Articles
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder
- Duration of Untreated Depression Predicts Depression Severity
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Elevated Dopamine Synthesis Capacity Observed in Both Bipolar and Schizophrenia
- SSRI Use Associated With Increased Type 2 Diabetes Risk in Young Adults
- Specialty Physicians Experiencing Lack of Income Growth
- Improved Patient-Provider Communication Needed Following Urgent Care Visits
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV